Matthew Anderson, MD
Critical Care Medicine · Austin, TXNPI 1023221959
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $69,993 of the $78,509 with a category attached, or 89.2%. 19 manufacturers reported payments, led by Medical Device Business Services, Inc. at 38.4% of the total. Among critical care medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $436.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$30K
- Ethicon Endo-surgery Inc.$28K
- Johnson & Johnson$19K
- GSK$522
- Sanofi$195
- Intuitive Surgical$141
- plus $441 from 13 others
Across 13 payments — averaging $18,149 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cepheid$236K
What the payments were for
- Consulting fees$69,99389%
- Travel & lodging$5,0886%
- Food & beverage$3,3664%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 28 | $30,182 |
| Ethicon Endo-surgery Inc. | 16 | $27,985 |
| Johnson & Johnson | 44 | $19,044 |
| GSK | 56 | $522 |
| Sanofi | 12 | $195 |
| Intuitive Surgical | 2 | $141 |
| Boehringer Ingelheim | 4 | $79 |
| Actelion Pharmaceuticals US, Inc. | 3 | $54 |
| AstraZeneca | 2 | $40 |
| GE HealthCare | 1 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $34 |
| Amgen | 1 | $34 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Gilead | 2 | $27 |
| Sunovion Pharmaceuticals Inc. | 3 | $25 |
| Inogen, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Olympus America Inc. | 1 | $18 |
| Merit Medical Systems Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$74,003
- MONARCH$1,099
How this compares
$78,509 in reported general payments places this provider in the 95th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 424 | $550,747 |
| OfevNintedanib Esylate | 26 | $330,161 |
| Fasenra PenBenralizumab | 24 | $135,835 |
| Breo ElliptaFluticasone/Vilanterol | 153 | $114,746 |
| Spiriva RespimatTiotropium Bromide | 86 | $77,411 |
| Pirfenidone | 28 | $65,526 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $57,293 |
| Advair HfaFluticasone Propion/Salmeterol | 51 | $33,279 |
| Arnuity ElliptaFluticasone Furoate | 79 | $29,201 |
| Spiriva HandihalerTiotropium Bromide | 34 | $28,534 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $21,860 |
| SymbicortBudesonide/Formoterol Fumarate | 50 | $21,461 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $18,889 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 420 | $16,605 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 57 | $16,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta | $522 | $729,731720 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $79 | $429,432137 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $40 | $78,75490 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in Austin
- William BartekAustin$284K
- Subramaniyam RajanAustin$98K
- John HinzeAustin$28K
- Steven DavidoffPlano$364K
- Edwin ParsleyHouston$283K
- Hector PayanEl Paso$245K
- Bindu AkkantiHouston$185K
- Faisal MasudHouston$155K
- Sergio Trevino CastilloHouston$133K
- Akinyinka AjelabiKingwood$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.